Navigation Links
Synthetic Biologics to Report Third Quarter 2013 Financial Results
Date:11/7/2013

ROCKVILLE, Md., Nov. 7, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it intends to release its financial results for the third quarter ended September 30, 2013 on Thursday, November 14, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130522/MM19465LOGO)

The Company will hold an investor conference call on Thursday, November 14, 2013, at 10:00 am EST. During the call, Jeffrey Riley, Synthetic Biologics' Chief Executive Officer, will provide a brief quarterly update of the Company's multiple sclerosis program and its anti-infective drug pipeline for infectious diseases, including its oral enzyme candidate for the prevention of C. difficile infections. C. Evan Ballantyne, Synthetic Biologics' Chief Financial Officer, will review the Company's financial results for the third quarter ended September 30, 2013.

Interested parties should call 1-877-870-4263 (U.S. toll free), 1-855-669-9657 (Canada toll free), or +1 412-317-0790 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=96920. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=96920 for 30 days after the call.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Atlantic Peptides, a Synthetic Peptide Manufacturer, Unveils Its New Website for Easier Navigation
2. Synthetic Biologics Responds to Recent CDC Report on Threat of "Super Bugs"
3. Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
4. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
5. Synthetic Biologics to Report Second Quarter 2013 Financial Results
6. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
7. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
8. Synthetic Biologics to Present at OneMedForum New York 2013
9. New England Biolabs supports iGEM synthetic biology competition
10. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
11. Intrexon Organizes Around New Synthetic Biology Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
Breaking Biology Technology:
(Date:5/23/2017)... , May 23, 2017  Hunova, the first robotic gym for the ... been officially launched in Genoa, Italy . The first ... and the USA . The technology was developed ... market by the IIT spin-off Movendo Technology thanks to a 10 million ... News Release, please click: ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext Inc., a global ... of a media edge server, the M820, which features the company,s ... recognition software provided by Tera Probe, Inc., will be showcased during ... at the NAB show at the Las Vegas ... ...
Breaking Biology News(10 mins):